Suvivin is a novel member of the inhibitor of apoptosis protein (IAP) family, which is known to be over-expressed in various carcinomas and associated with their biologically aggressive characteristics. The aim of this study was to investigate survivin expression in human medullary thyroid carcinoma ( 
Introduction
Suvivin is a novel member of the inhibitor of apoptosis protein (IAP) family, whose gene is located at chromosome 17q25. Survivin is reported to inhibit apoptosis triggered by various inducers such as Fas-Fas ligand pathway, caspase cascades, and chemotherapy (Ambrosini et al., 1997; LaCasse et al., 1998; Tamm et al., 1998; . Survivin is thought to help cells overcome the G2/M checkpoint against apoptosis due to its expression in the G2-M phase of the cell cycle and interaction with microtubules of the mitotic spindle (Li et al., 1998) .
Highly expressed survivin has been found in a growing number of carcinomas, such as colorectal adenocarcinoma, esophageal carcinoma, non-small cell lung carcinoma, pancreatic cancer, and melanoma, and demonstrated to be associated with biologically aggressive characteristics including unfavorable prognosis in some tumors (Kawasaki et al., 1998; Kato et al., 2001; Kren et al., 2004; Abd El-Hameed, 2005; Lee et al., 2005; Shinohara et al., 2005; Takeuchi et al., 2005) . In addition, the high Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells prevalence of survivin is also found in the premalignant lesions of skin carcinoma and uterine carcinoma (Grossman et al., 1999; Kim et al., 2002) . But it is not usually present in normal tissues and rarely found in mature tissues (Ambrosini et al., 1997; Zaffaroni et al., 2005) . These findings suggest that survivin may be potentially important in the development and/or progression of carcinomas.
Thyroid carcinoma (TC) is a representative malignancy originating from the endocrine organs. Thereinto, medullary thyroid carcinoma (MTC) is an aggressive tumor arising from neoplastic thyroid parafollicular C cells, accounting for 3-5% of all thyroid malignancies (Ball et al., 2001) . So far, in thyroid tumors, information on survivin overexpression is available in lymphoma and thyroid neoplasms including follicular adenoma, and follicular and papillary and anaplastic carcinomas (Sugawara et al., 2002; Ito et al., 2003) , but little in MTC. Moreover, in those thyroid neoplasms, Ito et al. (2003) found a significant relationship of the survivin expression with dedifferentiation, i.e. the anaplastic transformation of tumor cells, suggesting that survivin may be a potential target for anti-TC gene therapy.
In this study, we immunohistochemically examined survivin expression in human normal thyroid tissues, MTC, and a human MTC cell line, TT. Furthermore, in MTC, the correlations were analyzed between survivin expression and the clinicopathologic features including gender, age, tumor size, T stage, lymph node invasion, distant metastasis and TNM stage; in TT cells, survivin expression was confirmed by RT-PCR and Western blot analyses, and effects of antisurvivin oligonucleotides (ASODNs) on survivin expression, growth and viability, and apoptosis were investigated.
Materials and Methods

Clinical samples
Paraffin-embedded tissue samples of human normal thyroid (NT, n = 10) and medullary thyroid carcinoma (MTC, n = 10) were retrieved from storage at the Department of Pathology, China Medical University, China. The project was approved by the ethics committees of the hospital and informed consent was obtained from the patients or their first-degree relatives. The ten NT tissue samples had been obtained by autopsy. The other MTC samples were resected surgically between 1999 and 2003. The diagnoses for NT and MTC were confirmed histologically. Moreover, MTC was confirmed by the tumor marker calcitonin (CT) immunostaining. The autopsy specimens were obtained from cadavers of people with a mean age of 38 ± 12 years (range 20-54). The mean age with SD for the MTC patients was 43 ± 16 years (range 23-71). No patients had undergone preoperative radiotherapy or chemotherapy. Information regarding the clinicopathologic features of the 10 MTC patients, such as gender, age, tumor size, capsule invasion, adjacent organ involvement, lymph node invasion and distant metastasis at the time of surgery, was available. Based on these information, TNM staging for each tumor was reevaluated according to the TNM classification system recommended by the American Joint Committee on Cancer (AJCC) in 2002 (Greene et al., 2002) .
Cell line and cell culture
The human MTC cell line TT was obtained from Chinese Center for Typical Culture Collection. The cells were maintained in F12 culture medium (Gibco Co.) supplemented with 10% FCS at 37 o C in a 5% CO2 humidified atmosphere, fed every 3 days with complete medium, and subcultured when confluence was reached.
Immunohistochemical analyses of clinical samples and TT cell line
For clinical samples, four-m-thick paraffin sections were serially cut from paraffin-embedded tissues and deparaffinized following being mounted on slides. For TT cell line, cells (1 × 10 5 cells/well) were grown on 4-well chamber glass slides in complete F12 medium; the slides at 80-90% confluence were rinsed in PBS, dried well, and then fixed in 95% ethanol for 4 h at 4 o C. All slides were treated for three 5-minute cycles in a microwave oven at 500 W using 0.01 M pH 6.0 citrate buffer to unmask the antigens. Slides were then immersed in methanol containing 3% hydrogen peroxide for 5 min to block endogenous peroxidase activity. For immunohistochemical detection of survivin or CT, slides were incubated in a humid chamber overnight at 4 o C with 1:100 dilution of rabbit anti-human survivin monoclonal (Boster Biotechnology Co., Wuhan, China) or rabbit anti-human CT polyclonal (Maixin Biological Technology Co., Fuzhou, China) antibody. Bound antibodies were visualized using a SABC complex kit (Boster Biotechnology Co., Wuhan, China), which is based on streptavidin-biotin-peroxidase complex-binding technique, according to the manufacture's instruction. Diaminobenzidine was used as the chromogen. After the expected stain intensity developed, sections were lightly counterstained with hematoxylin. As negative controls, immunostaining was performed by incubating samples with PBS instead of the primary antibody.
Immunohistochemical evaluation
Cells were regarded as positive for survivin when immunoreactivity was clearly observed in their cytoplasms or nuclei. The immunohistochemical results with no positive cells were considered as negative, and those with positive cells as positive.
Treatment of TT cells with antisurvivin and control oligonucleotides 20-mer antisense oligonucleotides (ODNs) targeting human survivin mRNA was used as antisurvivin oligonucleotides (ASODNs) (Xia et al., 2002) . The reverse sequence of ASODNs was used as control ODNs (CODNs). The sequences of ODNs were 5'-CCCAGCCTTCCAGCTCCTTG-3' (ASODNs) and 5'-GTTCCTCGACCTTCCGACCC-3' (CODNs). The ASODNs and CODNs were synthesized in the form of phosphorothioate oligonucleotides by Sangon Biotechnology Inc. (Shanghai, China), and employed for transfections in TT cells. One day before transfection, TT cells (2 × 10 5 cells/well) were plated in 12-well tissue culture plates. Cells were rinsed with 2 ml of serum-free F12 medium before transfection. ODNs were delivered in the form of complexes with Lipofectin (Life Technologies, Inc.) according to the manufacturer's instructions. Briefly, ASODNs or CODNs and Lipofectin reagent at a charge ratio of 1:2 were aggregated for 15 min at room temperature. The prerinsed cells were treated with the above ODNs-Lipofectin mixture in serum-free F12 medium at a final ODNs concentration of 200-800 nM. After incubation for 24 h, the treating culture medium was replaced with fresh F12 medium, and cells were cultured for an additional 6h or longer. Untreated cells, Lipofectin-treated cells and CODNstreated cells were used as control groups in all experiments.
RT-PCR analysis of survivin expression in TT cells
For reverse transcription-polymerase chain reaction (RT-PCR) analysis, total RNA was extracted from cell cultures using Trizol reagents according to the manufacturer's recommendations (Life Technologies, Inc.), the quality and quantity of RNA were assessed at the absorbance 260/280 using a UV spectrophotometer (UV-310, Spectronic, UK), and all samples showed absorbency ratios ranging between 1.8 and 2.0. RT-PCR procedures were based on the manufacturer's instructions using a RT-PCR kit (AMV 2.1) (TakaRa Biotechnology Co., Ltd). Using 5 g total RNA, cDNAs were synthesized by RT and taken for PCR amplification. RT-PCR primers were ordered from Life Technologies. The primer sequences were 5'-ATGGGTGCCCCGACGTTG-3' (sense) and 5'-AGAGGCCTCAATCCATGG-3' (antisense) for survivin and 5'-ATCATGTTTGAGACCTTCAACA-3' (sense) and 5'-CATCTCTTGGTCGAAGTCCA-3' (antisense) for -actin used as internal control. Expected RT-PCR product sizes were 436 bp for survivin and 308 bp for -actin. PCR conditions comprised a predenaturation for 2 min at 94 o C, followed by 35 cycles of denaturation for 1 min at 94 o C, annealing for 30 s at 60 o C, and extension for 1 min at 72 o C. The PCR products were separated by electrophoresis on a 2% agarose gel. Gels were stained with ethidium bromide, destained, and photographed by the image analysis system ChemiImager 5500 (Alpha Innotech). The relative mRNA expression for each sample was calculated as the ratio of the integrated OD of survivin and that of -actin using the image software MetaMorph 5.0 (UIC). It was then normalized to that in untreated cell group taken as 100%.
Western Blotting analysis of survivin expression in TT cells
Cells were washed twice with ice-cold PBS, and lysed with 300 µl of lysis buffer solution (50 mM Tris-HCl, pH 7.4; 0.15 M NaCl; 1% Triton X-100, and 1 mM EDTA) containing a complete protease inhibitor cocktail. The lysate was sonicated six times for duration of 1 s, laid on ice for 15 min, and then centrifuged for 15 min at 15,000 rpm. The supernatants were stored at -20 o C until use. The concentration of protein in the supernatant was measured by the bicinchoninic acid protein assay reagent (Pierce Chemical Co., Rockford, IL) according to the manufacturer's suggestions. Equal amounts (40 µg) of proteins were electrophoresed through a 12% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred onto nitrocellulose membranes (Amersham International plc, Amersham, Bucks, UK). Membranes were blocked with 5% non-fat milk for 30 min at room temperature. They were then incubated with a rabbit anti-human monoclonal antibody to survivin (Boster Biotechnology Co., Ltd) overnight at 4 o C. Bound antibodies were revealed with a horseradish peroxidase-conjugated goat anti-rabbit IgG (Pierce Chemical Co.). The immunological complexes were visualized by reagents (ECL; Amersham Pharmacia Biotech, Freiburg, Germany). Each sample was also probed with an anti--actin antibody (Sigma-Aldrich Corp.) as loading control. Membranes were scanned using the ChemiImager 5500. The relative protein expression for each sample was calculated as the ratio of the integrated OD of survivin and that of -actin using the MetaMorph 5.0. It was then normalized to that in untreated cell group taken as 100%.
MTT assay for the effect of ASODNs on viability and growth of TT cells
For 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, TT cells were seeded in 12-well plates at a density designed to reach 70-80% confluence at the time of assay. The cells were then rinsed with F12 medium before transfection and treated with different concentrations of ASODNs (200-800 nM) starting on the 2nd day. After 24 h of treatment, 20 l of 5 mg/ml MTT (Sigma, USA) was added to each well of cells, and the plate was incubated for 4 h at 37 o C. The medium was removed, and the MTT crystals were solubilized in DMSO (Sigma) and subjected to centrifugation to pellet the cellular debris. Spectrophotometric absorbance of each sample was measured at 490 nm by an enzyme-linked immunosorbent assay reader (DG-3022A) using Ascent software (version 2.4). The percentage of viable cells was expressed as a percentage of the control average absorbance values obtained with untreated cells, and then normalized to that in untreated cell group taken as 100%.
Apoptotic analysis of TT cells
Three apoptotic assays were performed as below. (a) DNA laddering assay: Cells (1 × 10 6 ) were harvested via centrifugation and incubated at 50 o C overnight in a 100 l of lysis buffer [100 mM NaCl, 100 mM Tris-HCl (pH 8.0), 20 mM EDTA, 0.8% SDS, and 100 g/ml proteinase K]. The samples were then treated with 20 mg/ml RNase for 1 h at 37 o C, and precipitated with 0.5 mol/L NaCl and equivalent volume of isopropanol. After centrifugation at 16,000 × g for 15 min and rinsing with 70% ethanol, the pellets were dissolved in 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA. The DNA concentration was estimated by measuring the absorbance at 260 nm. DNA (5 g/lane) were electrophoresed on 1.5% agarose gels. The gels were then stained with ethidium bromide, destained, and photographed under UV transillumination. (b) Acridine orange/ethidium bromide (AO/EB) staining: Cells on the gelatincoated glass cover slips were prepared with different treatment as described above, fixed in 95% ethanol for 30 min, and then pre-treated with 1% acetic acid for 30 s before exposure to AO/EB dye mix (40 g/ml AO plus 100 g/ml EB) for 1 min. The apoptotic cells were observed under fluorescence microscopy with the excitation wavelength at 415 nm. 
Statistical analysis
Each experiment was repeated three different times. Data are presented as means ± SD, and analyzed with SPSS13.0. The concentration of ASODNs which inhibits 50% of survivin expression and cell proliferation (IC50) was determined by probit analysis. Fisher's exact test was employed to detect the correlations between the clinicopathologic features of MTC patients and survivin expression, and one-way ANOVA with Bonferroni's post hoc test was used as appropriate. A two-tailed P＜0.05 was considered statistically significant.
Results
Expression of survivin in NT, MTC and TT cells
All specimens from MTC patients showed positive immunoreactivity for CT, a MTC marker ( Figure 1A ). In NT, MTC and TT cell line, survivin protein expression was immunohistochemically analyzed. The negative controls and NT manifested no immunoreactivity for suvivin, but MTC and TT cells showed its immunoreactivities in cytoplasms and nuclei ( Figure 1B-D) . The positive incidence of survivin protein immunoreactivity was 80% (8 of 10 
Clinicopathologic features of MTC patients and their relationships with survivin expression
Clinicopathologic features of the MTC patients are presented in Table 1 . There were 10 MTC patients (6 females, 4 males) with a median age of 41 years (range, 23-71; mean ± SD, 43 ± 16). The tumor size ranged between 1.3 and 10.1 cm (median, 4.1; mean ± SD, 4.6 ± 2.8). Tumors were classified as T1, T2, T3, T4a, and T4b stages in 1 (10%), 3 (30%), 1 (10%), 4 (40%), and 1 (10%) cases respectively. Lymph node invasion were graded into N0, N1a, and N1b in 4 (40%), 4 (40%), and 2 (20%) cases respectively. Distant metastasis was detected in 1 (10%) patient. The TNM stages were I in 1 (10%) patient, II in 1 (10%), III in 2 (20%), IVA in 4 (40%), IVB in 1 (10%), and IVC in 1 (10%). No significant correlation was found between any of the above clinicopathologic features and survivin expression. 
Down-regulation of survivin expression by ASODNs in TT cells
To investigate the inhibitory effect of ASODNs on survivin expression, RT-PCR and Western blotting analyses were performed. No significant difference in survivin expression was found at both mRNA and protein levels between controls, i.e. untreated, Lipofectin-treated and CODNs-treated TT cells. However, as compared with controls, treatment with 200-800 nM ASODNs for 24 h significantly reduced survivin mRNA level by 15-75% with an IC50 of 494 nM and its protein level by 13-73% with an IC50 of 549 nM in a dose-dependant manner at 30 h after the start of transfection in TT cells (Figure 2 ).
Inhibitory effects of ASODNs on viability and growth of TT cells
As shown in Figure 3A , treatment of TT cells for 24 h with survivin ASODNs caused a dose-dependent decrease in cell viability and growth with an IC50 of 723 nM. The inhibition rates of cell proliferation exposed to 200 nM, 400 nM, 600 nM, and 800 nM survivin ASODNs for 24 h were 8%, 26%, 43% and 53% at 30 h after the start of transfection, respectively. Furthermore, concentrations of 400-800 Figure 3 . The effects of ASODNs on the viability and growth of TT cells. Following treatment for 24 h with an increasing concentration of ASODNs (200-800 nM), medium were replaced to F12 medium, and cells were cultured for an additional 6 h. Photographs were then taken, and cell viability was determined by MTT assay. Untreated, Lipofectin-treated, and CODNs-treated cells were used as controls. (A) MTT assay for cell viability. Each value is normalized to that in untreated cell group which was taken as 100%, and represents the mean ± SD ( a P ＜ 0.001, vs untreatment group; b P ＜ 0.001, vs Lipofectin group; c P ＜ 0.001, vs CODNs group at the same concentration by one-way ANOVA with Bonferroni's post hoc test). nM were found to significantly inhibit viability and growth in ASODNs-treated cells compared to those in controls, whereas no significant inhibitory effect was observed between controls at any concentration. The dose-dependant death induced by ASODN could also be revealed by detachment of TT cells from the culture surface ( Figure 3B and C, D, E, F, G).
Apoptotic induction by ASODNs in TT cells
To verify the effect of ASODNs on apoptosis of TT cells, three different methods including DNA laddering assay, AO/EB staining and flow cytometric cell cycle analysis, were adopted. DNA laddering assay showed detectable DNA ladders in ASODNstreated group, but not in controls ( Figure 4A ). AO/EB staining revealed apoptotic cells in ASODNs-treated group, but not in controls ( Figure 4B ). Flow cytometric cell cycle analysis found a significant dosedependant 1.8-11.1 fold increase in the apoptotic cell population in ASODNs-treated group relative to controls, with no noticeable apoptotic induction in controls ( Figure 4C ).
Time course of inhibition of survivin expression by ASODNs in TT cells
Indeed in our study, survivin expression in TT cells has shown a progressively suppressed response to an increasing concentration of ASODNs (200-800 nM) with a maximal depression by 800 nM ASODNs. The time course of suvivin inhibition by 800 nM ASODNs was then evaluated. Such experiments revealed an obvious inhibition of survivin by ASODNs at mRNA and protein levels starting within 12 h and persisting at least by 48 h after the start of transfection in ASODNs-treated group compared with controls ( Figure 5 ). No significant difference was, however, found between controls in inhibition of survivin expression. 
Discussion
Here we demonstrate for the first time that survivin protein expression is up-regulated in both MTC tissues and human MTC cell line TT relative to negative expression in NT tissues, suggesting it may play an important role in MTC. Survivin has been reported to be highly expressed in several human carcinomas, including lung, breast, colon, and ovary cancer, and scarcely expressed in differentiated normal tissues with the exception of some types of cells, such as basal colonic epithelium endothelial cells and neural stem cells (Ambrosini et al., 1997; Zaffaroni et al., 2005) . Furthermore, overexpression of survivin has been demonstrated to correlate with unfavorable prognosis in some tumors (Johnson & Howerth, 2004) .
Papillary, follicular, medullary, and anaplastic carcinoma constitute about 60%, 20%, 5% and 10% of thyroid malignant tumors, respectively. In thyroid neoplasms, Ito et al. found that the positive incidence of suvivin immunoreactivity was 11.1% (2 of 18 cases), 19.0% (4 of 21 cases), 22.5% (16 of 71 cases), and 84.2% (16 of 19 cases) in follicular adenoma, follicular carcinoma, papillary carcinoma, and anaplastic (undifferentiated) carcinoma, respectively, whereas they rarely observed survivin expression in normal thyroid follicules. Through further statistical analyses, they concluded that survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma (Ito et al., 2003) . In the present study, we observed a positive incidence of 80% (8 of 10 cases) in MTC and a high expression of suvivin in TT cells, but in NT, we found a negative incidence of 100% (10 of 10 cases) consistent with the finding by Ito et al. In MTC, we try to reveal the clinicopathologic significance of suvivin expression through its relationships with some clinicopathologic features, but no significant correlation was found between them, suggesting that suvivin expression may be a novel predictor of MTC evolution independent of those conventional clinicopathologic factors. As our preliminary observations on the relationships between suvivin expression and the clinicopathologic features of MTC are based on a very small number of patients, further study involving a large number of patients is necessary to clarify the clinicopathologic significance of suvivin expression in MTC.
In TT cells, we found ASODNs could significantly reduce survivin gene expression at mRNA and protein levels concomitant with a decrease in viability and growth of TT cells in a dose-dependent fashion. Further apoptotic analyses confirmed that the decrease in viability and growth was attributable to apoptotic cell death. As survivin is known to preferentially bind to and inhibit effector caspases, such as caspase-3 and caspase-7 (Tamm et al., 1998) , its reduction by ASODNs in TT cells may potentially contribute to the cell apoptosis. In addition, overt inhibitory effects on cell growth and notable induction of apoptosis by ASODNs have also been found in other tumor cell lines (Xia et al., 2002; Cao et al., 2004; Fuessel et al., 2004; . Thus, the survivin-targeted gene therapy using ASODNs may be one of potentially promising alternatives for treatment of tumors.
At present, therapy for MTC is mostly restricted to surgical removal of the tumor tissue, but residual MTC can be detectable in 56% of patients after surgery owing to the early metastatic nature of MTC (Evans et al., 1999; Orlandi et al., 2001) . In MTC, objective responses to other forms of therapy such as chemotherapy and radiotherapy are mostly insufficent, fewer than 20% (Petursson, 1988; Samaan et al., 1988; Wu et al., 1994; Brierley et al., 1996; Vitale et al., 2001) . Therefore MTC represents an attractive target for alternative gene therapeutic strategies, of which ASODNs may be considered as one of choices. Moreover, based on the finding of synergic effects of ASODNs in sensitizing cancer cells to chemotherapy and radiation therapy (Olie et al., 2000; Shinohara et al., 2004) , ASODNs in combination with other therapeutic strategies may be more powerful in treatment of MTC. In our TT cell line, the IC50 of ASODNs for tumor growth and viability is 723 nM, whereas it is 300nM in a lung carcinoma cell line A549 (Olie et al., 2000) , suggesting that lung cancer may be more sensitive to ASODNs as compared with MTC. In TT cells, through the time course analysis, we found a significant inhibition by 800nM ASODNs in survivin expression at both mRNA and protein levels, starting within 12 h and persisting over 48 h after the start of transfection. In a lung carcinoma cell line A549, Olie et al. observed an obvious reduction by 600 nM ASODNs in suvivin mRNA expression 20 h after the start of transfection (Olie et al., 2000) . In H28 and MS-1 mesothelioma cell lines, Xia et al. detected a noticeable decrease by 500 nM ASODNs in suvivin protein level 17 h after the start of transfection (Xia et al., 2002) . These results indicate an efficient role of ASODNs in inhibition of suvivin expression in various tumor cells.
In conclusion, our data show that: 1) survivin is highly expressed in MTC and a MTC cell line TT, suggesting its important role in MTC, 2) survivin expression is not significantly related to any of the clinicopathologic features of MTC, implying its role in MTC independent of those conventional clinicopathologic factors, and 3) ASODNs could down-regulate suvivin expression, decrease viability and growth, and induce apoptosis in TT cells, indicating its potential value in treatment of MTC.
